<DOC>
	<DOCNO>NCT01016509</DOCNO>
	<brief_summary>A multicentric study evaluate whether peri-procedural tight glycemic control angioplasty revascularization acute coronary syndrome ( ACS ) reduce circulate inflammatory cytokine thrombus formation hyperglycaemic patient . Moreover , investigator assess whether tight glycemic control first month coronary event reduces incidence coronary stent restenosis 6-months PCI .</brief_summary>
	<brief_title>Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis</brief_title>
	<detailed_description>The study design structure basis protocol Yale . Upon emergency ward admission , patient assign undergo prompt coronary revascularization . After PCI procedure , hyperglycemic patient randomly assign intensive glucose control ( IGC group ) treat conventional glucose control ( CGC group ) . In patient In CGC group , continuous insulin infusion 50 IU Actrapid HM ( Novo Nordisk ) 50 ml NaCl ( 0.9 % use Perfusor-FM pump ) start blood glucose level exceed 200 mg/dl adjust keep blood glucose 180 200 mg/dl . When blood glucose fell &lt; 180 mg/dl , insulin infusion taper eventually stop . In IGC group , insulin infusion start blood glucose level exceed 140 mg/dl adjust maintain glycemia 80-140 mg/dl . During insulin infusion , oral feeding stop parenteral nutrition ( 13±5 Kcal/kg-1/day-1 ) start . After start insulin infusion protocol glycemic control provide every hour order obtain three consecutive value within goal range . The infusion last stable glycemic goal ( ICG group : 80-140 mg/dl ; CGC group : 180-200 mg/dl ) least 24 h. After glycemic goal maintain 24 h , parenteral nutrition stop feed start accord European guideline . Subcutaneous insulin initiate cessation infusion . After discharge hospital , insulin give short-acting insulin meal long-acting insulin even 30 day PCI group . In IGC group , treatment goal fast blood glucose level 90-140 mg/dl non-fasting level &lt; 180 mg/dl . In CGC group , treatment goal fast blood glucose postprandial level &lt; 200 mg/dl . With regard full medical therapy , protocol state use concomitant treatment uniform possible accord evidence-based international guideline ACS . After 30 day PCI , patient establish diabetes newly diagnose diabetes manage follow 6 month PCI , outpatient , maintain HbA1c &lt; 7 % blood glucose level 90-140 mg/dl non-fasting level &lt; 180 mg/dl . Coronary Angiography Coronary angiogram baseline , immediately PCI , 6 month perform least 2 orthogonal view intracoronary nitroglycerin . Minimum lumen diameter ( MLD ) mean reference diameter ( RD ) , obtain average 5-mm segment proximal distal target lesion location , use calculate diameter stenosis follow : ( 1-MLD/RD ) X100 . Late loss change MLD final PCI follow-up . In-stent analysis confine stent , in-segment analysis include stent plus 5-mm segment proximal distal stent . Binary restenosis define &lt; 50 % diameter stenosis . Qualitative analysis do standard publish method . IVUS Imaging Analysis IVUS baseline , immediately PCI , 6 month perform iLab , Galaxy , ClearView In Vision Gold 20-MHz EagleEye catheter . IVUS image perform motorized pullback 0.5 mm/s include stent &gt; 5 mm segment proximal distal stent . IVUS study archive onto super-VHS tape , CD-ROM , DVD send independent , treatment-allocation- blind , IVUS core laboratory quantitative qualitative analysis validate planimetry software . Quantitative analysis include measurement every 1 mm external elastic membrane ( EEM ) , stent , lumen cross-sectional area ( CSAs ) . Plaque plus medium CSA calculate EEM minus lumen . Neointimal hyperplasia ( NIH ) calculate stent minus lumen . Once complete set CSA measurement obtain , intrastent stent-edge volume ( EEM , plaque plus medium , stent , lumen , NIH ) calculate Simpson 's rule normalize stent reference segment length . Percent net volume obstruction calculate NIH divide stent volume . Qualitative analysis include stent malapposition ( blood speckle behind stent strut ) , categorize persistent ( visible baseline follow-up ) , resolve ( visible baseline ) , late acquire ( visible follow-up ) ; intrastent plaque and/or thrombus protrusion ( IVUS reliably differentiate plaque thrombus protrude stent strut ) ; stent fracture ( absence strut one third stent circumference ) ; aneurysm ( lumen &gt; 50 % large proximal reference ) ; edge dissection .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>chest discomfort last least 15 min within last 24 h , new &gt; l mm STwave dynamic Twave change least two contiguous ECG lead , troponin I level 99th percentile 612 h onset chest pain patient refer cardiac catheterization laboratory within 24 h symptom . leave ventricular ejection fraction le 25 % , hemorrhagic diatheses , contraindication allergy aspirin , thienopyridines , history anaphylaxis response iodinate contrast medium , serum creatinine level 2.0 mg/dl ( 177 μmol/l ) , leukocyte count less 3500/mm3 , platelet count le 100,000/mm3 coexisting condition limit life expectancy le 24 month could affect patient 's compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>restenosis</keyword>
	<keyword>insulin</keyword>
	<keyword>hyperglycemia</keyword>
</DOC>